medRxiv · 24 Sept 2026 · Preprint · Open access

A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial

Pandey, Mirando + 7 more

Open access

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

MYDGF promotes pathological and physiological retinal angiogenesis via the Gαi1/3-Gab1-Akt-mTOR signaling.
Nature Communications · 23 June 2026 · Journal Article
MYDGF drives retinal angiogenesis through Gαi1/3-Gab1-Akt-mTOR signaling, promoting both pathological and physiological vessel growth in mice and humans.
- 1 opens in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42336863
Open in JClub
Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Suprachoroidal delivery of AL-001 achieves sustained aflibercept expression and superior efficacy with minimal inflammation in a nonhuman primate model of wet age-related macular degeneration.
- 1 opens in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42745920
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read